Please enable JavaScript in your web browser settings, under the site permissions section to unlock full site functionality. Click here for help.

Article Image - OPKO Health Acquires EirGen Pharma

Posted 28th May 2015

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

Scroll to keep reading

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

View Biography

Paul Heffernan, Legal Adviser OPKO Health

OPKO Health, Inc. is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than 40 others around the world.

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art high containment research and development, and manufacturing facility, is approved by the FDA, EMEA (European Health Authorities) and the PMDA (Japanese Health Authorities). High potency drugs such as those used for cancer chemotherapy are typically unsuitable for manufacture in normal multi-product facilities due to cross contamination risks.

To date, EirGen and its commercial partners have filed 10 product applications with the FDA and 5 each in Europe and Japan. EirGen has a strong research and development portfolio of over 20 niche, high barrier to entry drugs and, with access to additional capital that OPKO will provide, together with the benefits of Irish government programs to encourage research and development in Ireland, EirGen will rapidly expand its drug portfolio.

“EirGen Pharma is one of the leading developers and suppliers of high potency niche pharmaceutical products in the world,” said Phillip Frost, M.D. OPKO’s Chairman and CEO. “As FineTech, OPKO’s Israeli active pharmaceutical ingredient manufacturing subsidiary, is also focused on high potency drugs, an immediate business synergy is expected. EirGen also offers the significant benefit of potentially being able to manufacture OPKO’s current and future products in our own facilities, which we expect will result in even higher gross margins. The superb management, research and development, manufacturing and product distribution teams, along with state of the art facilities, together, will create an important, tax efficient base of operations for OPKO,” said Dr. Frost.

Categories: M&A, Strategy

You Might Also Like

The UK Cities with the Most Female Leaders

16/10/2023The UK Cities with the Most Female Leaders

A recent study, carried out by Instant Offices provides an in-depth look into the landscape of female leadership throughout the UK. The focus of this analysis spans various dimensions such as location, age, and industry sectors.

What Is Medical Negligence? What To Do If You Experience One

16/03/2023What Is Medical Negligence? What To Do If You Experience One

You expect the best care and results when you go to a hospital. However, sometimes things don’t go as anticipated. Your healthcare provider could make errors during treatment, diagnosis, or aftercare.

The Economic Benefits Of Investing In Portable Office Solutions

23/04/2024The Economic Benefits Of Investing In Portable Office Solutions

Being able to work anywhere is an arrangement that many organizations have been incorporating in their operations in the past few years.

Coeur Acquisition of Wharf Gold Mine

27/02/2015Coeur Acquisition of Wharf Gold Mine

Coeur Acquisition of Wharf Gold Mine Coeur Mining, Inc, a precious metals mining company listed on the Toronto and New York Stock exchanges, has acquired the Wharf gold mine located in Lead, South Dakota. The acquisition involved entering into a deﬁnitive ag

YFM Equity Partners announces £60m first close of its Buy-Out Fund II

12/06/2019YFM Equity Partners announces £60m first close of its Buy-Out Fund II

YFM Equity Partners (YFM) announces the first close of its Buy-Out-Fund II with £60m of investment committed. This follows the £45m raised for its Buy-Out Fund I, which had a final close in April 2017. Only two years later, and following the recent investmen

Seven Ways Geo-Economics Is Changing the Global Economy

27/02/2015Seven Ways Geo-Economics Is Changing the Global Economy

Report from the World Economic Forum's Global Agenda Council on Geo-economics identifies seven geo-economic trends that could decelerate or even reverse globalization.

How to Apply for a Hong Kong Business Registration Certificate: Routes, Fees and Deadlines

26/10/2026How to Apply for a Hong Kong Business Registration Certificate: Routes, Fees and Deadlines

Every business carried on in Hong Kong needs a Business Registration Certificate, but the route to one depends on how the business is set up. A new limited company gets it from the Companies Registry together with its Certificate of Incorporation. Sole p

Under Promise – Over Delivery

26/01/2017Under Promise – Over Delivery

Jean-Claude and Partners, winner of the 2016 Most Innovative Accountancy Firms for France offers an insight into this accounting firm, of which he is the managing director of.

Ready for New Challenges

29/06/2017Ready for New Challenges

Carlos Martín of MST Holding was delighted to receive the CTO of the Year – Spain accolade recently, after which we took the opportunity to profile the company and his crucial role within it.

View More Articles

Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

MORE BRANDS